A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
Latest Information Update: 18 Dec 2023
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Shenzhen Kangzhe Pharmaceutical
- 13 Dec 2023 According to a China Medical System media release, ILUMETRI (Tildrakizumab Injection) has been newly included in China's National Reimbursement Drug List(NRDL)
- 10 Apr 2023 Status changed from active, no longer recruiting to completed.
- 21 Jul 2021 Results published in the China Medical System Media Release.